Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus, Inc. (NASDAQ: EOLS) is a performance beauty company headquartered in Newport Beach, California. Established in 2012, Evolus is dedicated to providing innovative medical aesthetic products to physicians and their patients in the United States and Europe. The company's flagship product, Jeuveau, is a proprietary 900 kilodalton purified botulinum toxin type A formulation. It is specifically designed for the temporary improvement in the appearance of moderate to severe glabellar lines, commonly known as frown lines, in adults.
Evolus operates primarily in the self-pay aesthetic market, a unique segment where medical products are purchased by physicians and other customers and then sold to consumers or used in aesthetic procedures. This customer-centric approach positions Evolus to meet the growing demand for non-surgical cosmetic enhancements.
Recent Achievements:
- Successful expansion of Jeuveau sales across the United States and Europe.
- Strong partnerships with distribution partners in Canada, generating significant service revenue.
- Continued investment in research and development to enhance and expand their product offerings.
Current Projects:
- Exploring new formulations and applications for botulinum toxin type A to address other aesthetic and medical needs.
- Enhancing digital platforms to improve customer engagement and support for medical professionals.
With a firm commitment to providing high-quality aesthetic solutions, Evolus, Inc. is poised for future growth and innovation in the beauty industry.
Evolus, a performance beauty company, announced the grant of stock options and restricted stock units (RSUs) to 9 newly hired non-executive employees. The grants consist of options to purchase 30,778 shares and 29,546 RSUs under the 2023 Inducement Incentive Plan.
The stock options, with an exercise price of $11.69, have a 10-year term and vest over 4 years, while the RSUs vest 25% annually over four years. These measures were taken as inducement for new employees, in line with Nasdaq Listing Rule 5635(c)(4).
Evolus has announced positive topline results from a U.S. pivotal study for its dermal fillers, Evolysse™ Lift and Smooth. Presented at the 2024 SCALE Meeting, the study showed that both products met primary and secondary endpoints, demonstrating superiority over Restylane-L in improving nasolabial fold severity at multiple time points. The safety profiles of the products were similar to Restylane-L with no serious adverse events. Evolus plans to submit Premarket Approval applications to the FDA within the next 90 days, potentially expanding their market by 78%, complementing their neurotoxin Jeuveau®.
Evolus celebrates the fifth anniversary of its flagship product, Jeuveau®, at the Women's Wear Daily (WWD) Beauty CEO Summit, where CEO David Moatazedi speaks.
Jeuveau® has been the fastest-growing aesthetic neurotoxin in the U.S. over the last three years, emphasizing the company's market impact. Evolus aims to redefine beauty through its performance beauty approach, focusing on younger demographics. The summit highlights Evolus' role in driving growth and innovation in global beauty.
Moatazedi reflects on Evolus' progress, evolving from a single-product company to a multi-product innovator in the beauty aesthetics space.
Evolus, Inc. reported granting stock options and restricted stock units to 14 new non-executive employees under the 2023 Inducement Incentive Plan. The awards have a vesting commencement date of May 7, 2024, with stock options priced at $13.42 per share and a 10-year term. RSUs vest annually over 4 years. The grants are compliant with Nasdaq Listing Rule 5635(c)(4).
Evolus, Inc. announced that Sandra Beaver, the Chief Financial Officer, has been honored as the Public Company CFO of the Year by the Orange County Business Journal. Since joining in 2022, she has significantly contributed to the company's growth and success. Sandra supported the licensing agreements expanding the product portfolio by adding late-stage dermal fillers in the U.S. and European markets, increasing the addressable market by 78% to $6 billion. She also led the geographic expansion to Austria, Germany, and Italy, guiding the company to financial success and strategic decision-making.
Evolus, Inc. (NASDAQ: EOLS) reported Q1 2024 net revenue of $59.3 million, a 42% increase from Q1 2023. They aim for non-GAAP profitability in Q4 2024 and full year 2025. The company completed U.S. clinical trials for Evolysse® Lift and Smooth fillers, with FDA submission expected soon. Evolus reaffirmed full-year 2024 net revenue guidance of $255 million to $265 million, on track to achieve total net revenue goal of $700 million by 2028.
FAQ
What is the current stock price of Evolus (EOLS)?
What is the market cap of Evolus (EOLS)?
What is Evolus, Inc.?
What is Jeuveau?
Where is Evolus headquartered?
When was Evolus founded?
What market does Evolus primarily serve?
How does Evolus generate revenue?
What recent achievements has Evolus made?
What are Evolus's current projects?
Who are Evolus's primary customers?
What is the significance of Jeuveau's formulation?
